Stem Cells Market (By Product: Adult Stem Cells, Human Embryonic Stem Cells; By Application; By Technology; By Therapy; By End Use) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2022-2030

The global stem cells market was surpassed at USD 11.9 billion in 2021 and is expected to hit around USD 31.88 billion by 2030, growing at a CAGR of 11.57% from 2022 to 2030.

Report Highlights

• The adult stem cells segment dominated the market and accounted for the largest revenue share of 82.7% in 2021. 
• Regenerative medicine segment capturing the largest market share of 90.11% in 2021. 
• The cell acquisition segment captured the highest revenue share of 34.24% in 2021. 
• The allogenic therapy segment captured the largest revenue share of 59.06% in 2021.
• The pharmaceutical and biotechnology companies segment captured the largest revenue share of 52.81% in 2021. 
• North America accounted for the largest revenue share of 43.93% in 2021. 

Stem cells are cells that can differentiate into a variety of other cells, eventually forming organs or tissues. Many studies have been conducted over the years to assess the true potential of stem cells, leading to a variety of applications in the fields of genetic disease treatment, neurological disorders, oncology, and organ regeneration. The market is driven by the rising number of banks, growing focus on increasing therapeutic potential of these products, and extensive research for the development of regenerative medicines, among other factors.

The growing focus on regenerative therapies is fueling market expansion. iPSCs are becoming increasingly popular for the creation of customized cellular therapies, and opening up new possibilities in regenerative medicine. For instance, in September 2020, researchers from Duke-NUS and Monash University discovered the first stem cell that can aid in the treatment of placenta issues during pregnancy. The researchers devised a new method for producing induced trophoblast stem cells that can be used to generate placenta cells. The research will aid in the development of an in-vitro human placenta model and pave the way for future therapies.

Moreover, COVID-19 is acting as a catalyst for promoting the market growth. Several countries such as U.S., China, and Iran, have started conducting clinical trials using cellular therapies for treatment of COVID-19 infections. Furthermore, the use of cell therapy in the treatment of COVID-19 patients has yielded excellent results, which is fueling market expansion. In January 2020, a group of researchers in Beijing, China, tested stem cell treatment on patients to see if it was beneficial against COVID-19. The study found that administering intravenous clinical-grade MSCs to COVID-19 patients during first trial of treatment, improved their functional results and promoted enhanced recovery. 

Increasing prevalence of cancer is one of the key factors contributing to the growth over the forecast period. Failure of combination therapy and chemotherapy for treatment of cancer has led to the shift in preference of physicians from such therapies to autologous and allogeneic stem cell therapy, thereby boosting the growth. Moreover, key market players and the government bodies are continuously investing in cancer research. For instance, in November 2021, California Institute for Regenerative Medicine invested USD 4 million in therapy targeting patients with acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) 

Introduction of novel technologies for the usage and adoption of cell based therapy is expected to boost the growth over the forecast period. Automation in adult stem cell & cord blood processing and storage are the key technologies expected to positively influence the market growth. For instance, various scientists are aiming for the approval of safe, and successful treatments using stem cells in a broad range of diseases. In 2021, companies such as Biotech Cellino invested USD 75 million in an effort to merge Artificial Intelligence technology for the development of automated stem cell manufacturing, that has the ability to regularizing access to cell treatments while aiming to be cost effective. 

On the other hand, high cost of therapy is expected to hinder the market growth. For example, Bio informant, a stem cell research firm, reported that the cost of stem cell therapy ranges between USD 5,000 and USD 8,000 per patient, with some cases costing as much as USD 25,000 or more depending on the complexity of the procedure. Furthermore, restrictions on stem cell research activities have traditionally hampered embryonic stem cell growth, resulting in a meager share of the total market despite its advantages. 

Scope of The Report

Product Insights

The adult stem cells segment dominated the market and accounted for the largest revenue share of 82.7% in 2021. These adult stem cells do not involve the destruction of embryos, which is the case in embryonic stem cells. Furthermore, there is no risk of graft rejection in the case of adult stem cells. Development of cell banking services and advancements in bio preservation and cryopreservation are expected to further boost the demand for adult stem cells. Lesser ethical concerns surrounding adult cells further propel the growth of this segment. Benefits of adult stem cell banking such as capacity for autologous transformation, low risk of tumor formation, and availability of established treatment options are factors that expected to boost the growth of this segment during the forecast period.

Mesenchymal Stem Cells (MSCs), hematopoietic stem cells, epithelial/skin stem cells and neural stem cells, are all subtypes of ASCs. The MSC segment is expected to witness the fastest CAGR during the forecast period due to its use in autologous transplantation, substantial clinical trials which demonstrated its application for treating various diseases, and extensive ongoing research to investigate its therapeutic applications.

The induced pluripotent stem cells segment is expected to witness the fastest CAGR during 2022 to 2030, owing to increased investment in developing regenerative medicines using induced pluripotent stem cells, ensured reproducibility and maintenance, ability to differentiate into all cell types, and high proliferative ability. Many leading companies are also expanding services related to iPSCs as their importance in the treatment of various diseases grows. For instance, in January 2021, REPROCELL launched a new personalized induced pluripotent stem cells production service for generating patient-specific iPSC. The service will assist in the preparation and storage of an individual's iPSCs for the development of regenerative medicines to treat future illnesses or injury. They are developed from mature cells using ready-to-use RNA reprogramming technology.

Application Insights

Regenerative medicine and drug discovery and development are two applications within the application segment. Increased approvals for clinical trials on stem cell therapies targeting various diseases have resulted in regenerative medicine segment capturing the largest market share of 90.11% in 2021. Longeveron LLC, for example, announced in June 2020 that Japan's Pharmaceutical and Medical Devices Agency (PMDA) had approved the start of Phase 2 clinical trial to evaluate the safety and efficacy of their mesenchymal stem cells that can be used to treat aging frailty.

Furthermore, several governments are heavily investing in the development of regenerative medicines. For instance, the Government of Canada invested around USD 6.9 million in regenerative medicine research in March 2020. This fund will be used to support nine translational projects and four clinical trials aimed at developing new therapies in the field of regenerative medicine. The developed regenerative medicines will aid in the treatment of a variety of blood disorders, heart diseases, diabetes, and vision loss.

From 2022 to 2030, the drug discovery and development segment is expected to grow at a fastest CAGR. As it is useful in studying human disease etiology, identifying pathological mechanisms, and developing therapeutic strategies for tackling various diseases, market products are seeing increased penetration across drug discovery process. Because they can mimic patients' molecular and cellular phenotypes, iPSC-based models are preferred over phenotypic screening. Pharmaceutical companies can use these to test hypothesized drug mechanisms in vitro in a cost-effective manner prior to conducting clinical trials.

Technology Insights

The cell acquisition segment captured the highest revenue share of 34.24% in 2021. Discovery of embryonic stem cells has paved way for development of novel treatments for several diseases. These cells are pluripotent in nature and can be used to differentiate many cell types in the body. However, obtaining embryonic cells directly from the embryo has raised ethical concerns. Hence, researchers discovered an alternative—iPS cells. For instance, in September 2020, a collaborative team of researchers from Singapore and Australia studied the molecular changes, which occurs when adult skin cells become induced pluripotent stem cells (iPSCs). This led to the creation of new stem cells that could produce placenta tissue which could possibly lead to the development of new treatments for placenta complications arising during pregnancy.

The cell acquisition segment is further segmented into bone marrow harvest, umbilical blood cord and apheresis. The bone marrow harvest segment captured highest revenue share owing to the factors such as rising awareness, increasing prevalence of blood cancer, and easy access to bone marrow transplantation therapy.

Therapy Insights

The allogenic therapy segment captured the largest revenue share of 59.06% in 2021 with regards to revenue generation. Factors such as high pricing and growth in stem cell banking have contributed to the growth of this segment. Moreover, many cell therapy companies are shifting their business toward development of allogenic cell therapy products. This, in turn, is expected to result in the significant growth of this segment.

In addition, strategic activities by key market players to strengthen their product portfolio will further offer lucrative opportunities in the review period. For instance, In March 2021, Acepodia, announced the closing of its USD 47 million Series B financing to advance the pipeline of allogenic cell therapy candidates. In June 2022, Immatics and Bristol Myers Squibb expanded its strategic alliance for the development of gamma delta allogeneic cell therapy programs.

However, autologous therapy is expected to witness a lucrative rate throughout the forecast period. This is primarily due to low risk of complications associated with autologous treatment. Other factors anticipated to propel the growth of this segment include affordability, improved survival rate of patients, no need for identifying an HLA-matched donor, no risk of graft-versus-host diseases. Furthermore, autologous MSCs are investigated for their potential in the treatment of osteoarthritis as they can differentiate into cartilage and bone tissues.

MSCs have the ability to migrate to the site of injury, promote tissue repair by releasing anabolic cytokines, inhibit pro-inflammatory pathways, and differentiate into specialized connective tissues. Thus, adoption of autologous MSCs in regenerative medicine has increased, which is expected to propel the market growth during the forecast period.

End-user Insights

The pharmaceutical and biotechnology companies segment captured the largest revenue share of 52.81% in 2021. Some of the factors that can be attributed to the segment's share are rising prevalence of chronic disease, increase in clinical trials, upsurge in strategic activities along with improvements in healthcare services. For instance, in August 2022, StemCyte, Inc. obtained approval from U.S. FDA for their Phase II clinical trial for Post-COVID Syndrome using umbilical cord blood stem cell therapy. Moreover, in April 2022, US FDA granted clearance to BioCardia’s Investigational New Drug (IND) application to initiate a Phase I/II clinical trial of BCDA-04 in adults improving from acute respiratory distress syndrome linked with COVID-19.

Moreover, increasing number of clinical trials coupled with approval of stem cell-based therapies from regulatory bodies will further offer lucrative opportunities. For instance, there are around 5,000 listed clinical trials involved in stem cells research on ClinicalTrials.gov, with new clinical trials being offered every day in this field.

Regional Insights

North America accounted for the largest revenue share of 43.93% in 2021. Presence of innovators and key market players has resulted into higher penetration of market products in the region. North America leads the market owing to strong biotechnology industry, presence of key players, extensive R&D and promotion of personalized medicines. The region accounts for the highest revenue share. Moreover, growth in this region can be further attributed to rising government initiative for promoting stem cell therapies. For instance, in March 2020, the government of Canada invested around USD 7 million in regenerative medicine and stem cell research. It will support 9 transnational projects and 4 clinical trials in the country for growing regenerative medicine sector.

Asia Pacific is expected to witness a rapid rate owing to strong product pipelines of therapies based on stem cells and a huge patient population base. Stem cells market is expected to grow at a rapid rate due to the increasing incidence rate of diseases such as cancer, neurological disorders, and diabetes. Moreover, government funding to accelerate research on stem cell further strengthens the growth of this region. For instance, In February 2022, the government of India has set up the state-of-the-art stem cell research facilities in 40 leading health research and educational institutions. The government has also spent USD 80 million through Indian Council of Medical Research (ICMR) in the last three years under certain research projects.

Key Players

• Advanced Cell Technology Inc.
• STEMCELL Technologies Inc.
• Cellular Engineering Technologies Inc.
• CellGenix GmbH    
• PromoCell GmbH
• Kite Pharma
• Lonza
• Cellartis AB
• Angel Biotechnology
• Brainstorm Cell Therapeutics
• Celgene Corporation
• Osiris Therapeutics
• Genea Biocells
• Bioheart Inc.
• Waisman Biomanufacturing
• Tigenix
• Caladrius Biosciences
• Gamida Cell 

Market Segmentation

• By Product Outlook
• Adult Stem Cells (ASCs)

• Hematopoietic
• Mesenchymal
• Neural
• Epithelial/Skin
• Others
• Human Embryonic Stem Cells (HESCs)
• Induced Pluripotent Stem Cells (iPSCs)
• Very Small Embryonic Like Stem Cells
• By Application Outlook
• Regenerative Medicine
• Neurology
• Orthopedics
• Oncology
• Hematology
• Cardiovascular and Myocardial Infraction
• Injuries
• Diabetes
• Liver Disorder
• Incontinence
• Others
• Drug Discovery And Development
• By Technology Outlook
• Cell Acquisition
• Bone Marrow Harvest
• Umbilical Blood Cord
• Apheresis
• Cell Production
• Therapeutic Cloning
• In-vitro Fertilization
• Cell Culture
• Isolation
• Cryopreservation
• Expansion And Sub-Culture
• By Therapy Outlook
• Autologous
• Allogenic
• By End-user Outlook
• Pharmaceutical & Biotechnology Companies
• Hospitals & Cell Banks
• Academic & Research Institutes
• By Regional Outlook
• North America
• U.S.
• Canada
• Europe
• U.K.
• Germany
• France
• Italy
• Spain
• Asia Pacific
• China
• Japan
• India
• South Korea
• Australia
• Latin America
• Brazil
• Mexico
• Argentina
• Middle East and Africa
• South Africa
• Saudi Arabia
• UAE